The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

Those include GLP-1s for obesity such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which both carry hefty price tags of roughly $1,000 per month before insurance and other rebates.

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

The latest plan to tackle obesity in the UK could also help to get people back into work, but what are the risks?

The latest plan to tackle obesity in the UK could also help to get people back into work, but what are the risks?